June 4, 2026
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
May 28, 2026
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
April 30, 2026
Immutep Quarterly Activities Report Q3 FY26
Immutep Receives Nasdaq Notice of Bid Price Deficiency
April 22, 2026
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
April 15, 2026
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
EULAR 2026 – IMP761, a novel immunosuppressive LAG-3 agonist antibody in the clinic
May 31, 2026
ASCO 2026 – Eftilagimod alfa, an APC activator via MHC class II, induced lymphocyte activation linked to improved survival in metastatic cancer patients
February 20, 2026
Immutep Corporate Presentation
December 2, 2025
SABCS 2025 – Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003
November 13, 2025
CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)
October 19, 2025
ESMO Congress 2025 – EFTISARC-NEO (Soft Tissue Sarcoma)
Sorry, this block could not be loaded. Please contact your site administrator.
Please fill in your details and marketing permissions below. * indicates required.
Immutep Limited will use the information you provide on this form to be in touch with you and to provide updates and marketing. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at immutep@citadelmagnus.com.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices.
